Efalizumab-associated thrombocytopenia

Journal of the American Academy of Dermatology

Volumn 57, Issue 4, 2007, Pages 707-710

  Hostetler, Sarah Grim ^a   Zirwas, Matthew ^b   Bechtel, Mark A ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CORTICOSTEROID; EFALIZUMAB; HEMOGLOBIN; IMMUNOGLOBULIN; LEVOTHYROXINE; MONTELUKAST; SIMVASTATIN;

ADULT; APHTHOUS ULCER; CASE REPORT; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEADACHE; HUMAN; IMMUNOTHERAPY; MOUTH ULCER; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW; SKIN BRUISING; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VAGINA BLEEDING;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HEMORRHAGE; HUMANS; MIDDLE AGED; PSORIASIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 34548530602     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.05.042     Document Type: Review

References (9)

1. Raptiva [efalizumab] prescribing information (2005), Genentech, Inc, South San Francisco (CA). http://www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf Accessed January 19, 2006
2. Gottlieb A., Hamilton T., Caro I., Kwon P., Compton P., and Leonardi C. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54 Suppl (2006) S154-S163
3. Leonardi C., Papp K., Gordon K., Menter A., Feldman S.R., Caro I., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 (2005) 425-433
4. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opinion on Drug Safety 5 (2006) 197-209
5. van den Bemt P.M., Meyboom R., and Egberts A. Drug-induced immune thrombocytopenia. Drug Safety 27 (2004) 1243-1252
6. Winkelstein A., and Kiss J. Immunohematologic disorders. JAMA 278 (1997) 1982-1992
7. Warkentin T., and Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 143 (2005) 761-763
8. Anonymous. In: Raptiva (efalizumab). Dermatologic and ophthalmologic drugs advisory committee meeting; September 9, 2003; South San Francisco (CA): Genetech, Inc.
9. Sterry W., Stingl G., Langley R., Zacharie H., Lahfa M., Giannetti A., et al. Clinical experience acquired with raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from extended treatment in an international, phase III, placebo-controlled trial. J Dtsch Dermatol Ges 4 (2006) 947-956